has been shown to be effective with a variety of different antibodies conjugated to the same IR700 dye. [5] [6] [7] [8] [9] [10] The cell killing after NIR-PIT is rapid and results in necrotic/immunogenic cell death. 9, 11 A first-inhuman clinical trial of NIR-PIT in recurrent head and neck cancer patients employed an EGFR-targeted APC, cetuximab-IR700
(https://clinicaltrials.gov/ct2/show/NCT02422979); a phase 2 trial was recently completed and fast-track designation was received from the US FDA for a phase 3 trial beginning in 2018. In the phase 1/2 trial, patients were injected with cextuximab-IR700 conjugate, referred to as RM-1929 in the study. Approximately 24 hours later, the tumor was exposed to NIR light by means of a laser at a wavelength of 690 nm, which is absorbed by IR700. Very few side effects were seen and many patients experienced dramatic reductions in tumor size. Formal clinical results are still pending.
The therapeutic effects of NIR-PIT depend on access of the APC to the target tissue and the ability to deliver NIR light to that tissue.
NIR light can be easily delivered to lesions in the mouth and skin by means of an external light source. However, in more deeply located tumors light is rapidly attenuated, 12 so that it must be delivered by interstitial light fibers placed within the tumor. In some body cavities, such as the peritoneum and thorax, light theoretically could be delivered into the cavity and diffused so that wide surface areas are exposed. It is important to note that the NIR light therapy is not thermal or destructive by itself so that it can be delivered safely to normal tissue without toxicity.
A solution to delivering NIR light to a body cavity such as the peritoneum is to introduce light fibers with distal optical diffusers, using needles or endoscopes. After prior injection of the APC, peritoneal metastases could bind the agent and then NIR light administered via endoscopic optical fiber diffuser could deliver sufficient light to treat in a relatively minimally invasive way.
Near infrared photoimmunotherapy has been shown to be effective with a variety of different APC in animal models using superficial NIR light illumination. 4, [6] [7] [8] [9] [10] Although the feasibility of optical diffuser light delivery has been tested, 13 this technology has not been integrated into an endoscopically guided therapy. In this study, we investigate the efficacy of endoscopic NIR-PIT using a fiber optic diffuser for treating gastric cancer with PD in a mouse model.
| MATERIALS AND METHODS

| Reagents
Water soluble, silica-phthalocyanine derivative, IRDye 700DX NHS ester, was obtained from LI-COR Biosciences (Lincoln, NE, USA).
Trastuzumab, 95% humanized IgG 1 mAb directed against HER2, was purchased from Genentech (South San Francisco, CA, USA). All other chemicals were of reagent grade.
| Synthesis of IR700-conjugated trastuzumab
Conjugation of dye with mAb was performed according to a previous report. 4 In brief, trastuzumab (1.0 mg, 6.8 nmol) was incubated with IR700 NHS ester (60.2 lg, 30.8 nmol) in 0.1 mol/L Na 2 HPO 4 (pH 8.6) at room temperature for 1 hour. 
| In vivo near infrared photoimmunotherapy
To generate the disseminated peritoneal cancer mouse model, For in vivo bioluminescence imaging (BLI), D-luciferin (15 mg/mL, 200 lL) was injected intraperitoneally and the mice were imaged F I G U R E 1 Multi-color fluorescence mini-endoscopic system and near infrared photoimmunotherapy (NIR-PIT) procedure. A, Multi-color fluorescence imaging system is based on a clinically available fiber optic endoscope and light source. Excitation light is provided by multi-band excitation filters. Endoscopic images were obtained via a beam splitter, where the white light images were detected using the color-CCD camera and the fluorescence images were filtered by multi-color emission filters and detected with an (EM)-CCD camera. Both images are displayed side by side on the monitor. B, Cylindrical light diffuser with an NIR laser system was used. The cylindrical light diffuser was used through the endoscope. C, The endoscope was inserted into abdominal cavity through a small lower abdominal incision, and the abdominal cavity was inflated with air. Peritoneal cavity was exposed to NIR laser light using the optical diffuser under endoscopic guidance (Photon Imager) for luciferase activity (photons/min). Regions of interest (ROIs) were set for the entire abdomen to quantify the light flux. The ROIs were also placed on adjacent non-tumor regions as background. Average light flux of each ROI was calculated.
| Histological analysis
Real-time tumor biopsies were performed through the endoscope using biopsy forceps (FB-56D-1, Olympus, Tokyo, Japan) beginning 6 hours after NIR-PIT. Mice were euthanized with an overdose of carbon dioxide after the biopsies. Biopsy specimens were fixed for at least 24 hours with 10% formalin. Paraffin-embedded sections were stained with H&E. Post NIR-PIT tissue microscopy (BX61;
Olympus America, Melville, NY, USA) was then performed.
| Statistical analysis
Data are expressed as means AE SEM from a minimum of 10 experiments. Statistical analyses were carried out using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA). For multiple comparisons, ANOVA followed by Tukey's correction for multiple comparisons was used. A P-value of < .05 was considered statistically significant.
3 | RESULTS
| In vivo fluorescence endoscopy and histological analysis
The treatment and imaging regimen is shown in Figure 2A .
Implanted intraperitoneal disseminated tumors were evaluated by white light and endoscopic fluorescence imaging ( Figure 2B , C).
Tumor-targeted NIR-PIT was achieved using the fiber optic diffuser under endoscopic guidance ( Figure 2B and Video S1) Fluorescence endoscopy demonstrated multiple 1-3 mm intraperitoneal disseminated nodules based on GFP fluorescence. After tra-IR700 injection the implanted intraperitoneal disseminated tumors demonstrated IR700 fluorescence which co-localized with GFP ( Figure 2C ; tra-IR700 i.v. only and endoscopic NIR-PIT group). In contrast, no IR700 fluorescence was observed in tumors without tra-IR700 injection ( Figure 2C ; control and NIR light only group). These results demonstrate that intravenous injection of tra-IR700 was able to bind to intraperitoneal implants with preserved fluorescence capabilities. In animals undergoing endoscopic NIR-PIT, IR700 fluorescence signal in tumors diminished due to a combination of cytoreduction caused by NIR-PIT and partial photo-bleaching of IR700 ( Figure 2C ; endoscopic NIR-PIT group).
Real-time tumor biopsies were performed with biopsy forceps 6 hours after NIR-PIT (Video S2). H&E staining of NIR-PIT-treated N87GFP-luc tumors revealed diffuse necrosis and micro-hemorrhage, with scattered clusters of live but damaged tumor cells, while no obvious damage was observed in any of the control groups (Figure 2D ).
| In vivo endoscopic near infrared photoimmunotherapy
The treatment and imaging regimen of NIR-PIT is shown in Figure 3A. IR700 fluorescence signal decreased immediately after NIR light exposure ( Figure 3B ). In contrast, no significant changes of GFP fluorescence signal were shown after NIR light exposure ( Figure 3B ).
After treatment with NIR-PIT the bioluminescence of tumors decreased ( Figure 3C ). Quantitative luciferase activity decreased significantly in the endoscopic NIR-PIT group compared with the other control groups (P < .01) ( Figure 3D ). In contrast, luciferase activity of tumors in the control groups increased.
| DISCUSSION
Despite recent advances in chemotherapy and molecularly-targeted therapies directed against advanced gastric cancer, the prognosis of patients with disseminated peritoneal gastric cancer remains poor. There are several preconditions for successful NIR-PIT in vivo.
First, therapeutic effects induced by NIR-PIT depend on expression levels of the antigen on the target tumor as well as accessibility of the APC to the target. 6, 9 In vivo fluorescence endoscopy clearly showed IR700 fluorescence within peritoneal implants 24 hours after intravenous injection of tra-IR700 and IR700 signal co-localized with GFP, while no IR700 fluorescence signal was observed in tumors without tra-IR700 injection, as shown in Figure 2 . These results demonstrate that intravenous injection of tra-IR700 was able to penetrate into intraperitoneal implants via the vascular system.
Thus, the conjugate tra-IR700 proved to be an effective agent for treating an EGFR-expressing tumor with NIR-PIT. Another pre-requisite for successful NIR-PIT is the ability to deliver NIR light. In a clinical situation, peritoneal implants would have to be exposed to NIR
light either during open surgery or via fiber optic laparoscope. The latter is less invasive and likely to lead to faster patient recovery. As shown in Figure 1 , a fiber optic diffuser is introduced into the peritoneal cavity via an endoscope. Similarly, the fiber optic light diffuser could be placed within or near the tumor using laparoscopy, bronchoscopy or cystoscopy depending on the clinical situation. Such procedures could be performed more easily in human patients than in mouse models because an endoscopy or a laparoscopy can be conducted with better flexibility in greater peritoneal space in human
patients. Therefore, peritoneally disseminated tumors in most of the peritoneal cavity could be covered with NIR-PIT using laparoscopic procedures in human cancer patients.
Under fluorescence imaging, the conjugate tra-IR700 achieved a sufficient target-to-background ratio (TBR) to be readily identified (Figure 2 ), indicating that it may be possible to use fluorescence imaging during surgical or endoscopic procedures to identify cancers that are amenable to NIR-PIT. Therapeutic amounts of NIR light induce immediate cell membrane damage and death, which reduces the IR700 signal (Figures 2 and 3) . Loss of IR700 fluorescence implies both cell death and photobleaching, a sign that NIR light has activated the APC on the target. Using endoscopic fluorescence imaging, the operator is provided with immediate feedback regarding the effectiveness of the initial treatment and information about untreated targets.
Near infrared photoimmunotherapy differs from conventional photodynamic therapy (PDT) in several aspects. PDT produces substantially more toxicity due to the non-specificity of the photosensitizer which accumulates in tumor and non-tumor tissue. Light activation causes on-target and off-target damage, resulting in dose limiting toxicities. Porphyrin photosensitizers used in PDT do not selectively target cancer at the cellular level. [14] [15] [16] Precise control of laser irradiation during treatment is difficult to achieve, resulting in damage to surrounding healthy organs and/or blood vessels.
Recently, flexible coaxial laser endoscopy, which localizes the laser illumination only to the selected tumor target, with minimal illumination of the surrounding tissue was reported on. 17, 18 While this improves the safety of PDT there is still collateral damage. Moreover, after injection of modern porphyrin derivatives, the patient remains systemically photosensitive for over a week. 19 In contrast, PIT is set to 100) showed a significant decrease in endoscopic NIR-PIT groups compared with the 3 control groups (n ≥ 10, **P < .01 vs other groups, by Tukey's t test with ANOVA). Luciferase activity of tumor in other control groups showed an increase extend these studies to multiple NIR-PIT sessions and to monitor the long-term course in appropriate large animal models.
In conclusion, endoscopic NIR-PIT successfully treated PD of gastric cancer. Endoscopic NIR-PIT could be a promising method for treating PD using fiber optic diffusers to deliver the activating light.
In clinical settings, NIR light could be delivered in a similar manner using customized endoscopes to accommodate a number of anatomic sites throughout the body in which it is possible to insert endoscopic devices.
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